e-Drug3D

1979

VOXELOTOR

DISCONTINUED

INN
VOXELOTOR

cas 1446321-46-5

CLASS

BLOOD
A HEMOGLOBIN S POLYMERIZATION INHIBITOR
TREATMENT OF SICKLE CELL DISEASE

ROUTE (list)

ORAL

ATC code

B06AX03

PK parameters

Tmax 2 HOUR
Cmax 11.3 MILLIMOLAR
VD 338 LITER
Cl 6.7 LITER / HOUR
PPB 99.8 PERCENT
t1/2 35.5 HOUR

Solubility

INSOLUBLE IN WATER (APPROXIMATELY 0.03 MILLIGRAM PER MILLILITER)

Target

TARGET HEMOGLOBIN (HBS)

DrugCentral

hemoglobin subunit alpha UNIPROT P69905 HBA1

Download SDF file

Benzaldehyde, 2-hydroxy-6-[[2-[1-(1-methylethyl)-1H-pyrazol-5-yl]-3-pyridinyl]methoxy]-

Formula:
C19H19N3O3

Calculated chemical properties:

MW 337.37
NB_atoms 25
XLogP 3.62
PSA 69.959
NB_HD 1
NB_HA 6
fsp3 0.21
Lipinski(0=no;1=yes) 1

FDA
NDA 213137 (label) INN (VOXELOTOR) OXBRYTA (GLOBAL BLOOD THERAPS) APPROVAL= AP YEAR= 2019 NEWMOLECULARENTITY DISCONTINUED
NDA 216157 (label) INN (VOXELOTOR) OXBRYTA (GLOBAL BLOOD THERAPS) APPROVAL= AP YEAR= 2021 DISCONTINUED